Karolinska Institutet, Stockholm | Sweden
Many DNA damaging anti-cancer drugs cause replication-associated DNA damage that kills cancer cells. This is an effective way of treating cancer, but the problem is that also normal cells are damaged. Our strategy is to exploit the high level of DNA damage in cancer cells and prevent the repair of these lesions. Using DNA repair inhibitors, we can selectively introduce toxic DNA damage to cancer cells.
Keywords: Homologous recombination / DNA repair / DNA replication / DNA damage response / anti-cancer treatments